Reduction in staphylococcus aureus growth and exotoxin production and in vaginal interleukin 8 levels due to glycerol monolaurate in tampons

Clinical Infectious Diseases

Volumn 49, Issue 11, 2009, Pages 1711-1717

  Strandberg, Kristi L ^a   Peterson, Marnie L ^b   Schaefers, Matthew M ^b   Case, Laura C ^a   Pack, Melinda C ^c   Chase, David J ^c   Schlievert, Patrick M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXOTOXIN; GLYCEROL DERIVATIVE; GLYCEROL MONOLAURATE; INTERLEUKIN 8; STAPHYLOCOCCUS TOXIN; TOXIC SHOCK SYNDROME TOXIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM DETECTION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MENSTRUATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS; TAMPON; TOXIC SHOCK SYNDROME; TOXIN ANALYSIS; VAGINA;

ADOLESCENT; ADULT; BACTERIAL TOXINS; CARIOSTATIC AGENTS; ENTEROTOXINS; FEMALE; HUMANS; INTERLEUKIN-8; LAURATES; MENSTRUAL HYGIENE PRODUCTS; MONOGLYCERIDES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; VAGINA; YOUNG ADULT;

EID: 72849134568     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/644614     Document Type: Article

References (38)

1. Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980; 303:1429-1435
2. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55: 77-104. (Pubitemid 32978101) (Pubitemid 32978101)
3. Shands KN, Schmid GP, Dan BB, et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980; 303:1436-1442
4. Schlievert PM. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1986; 1:1149-1150
5. Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 1981; 143: 509-516 (Pubitemid 11111260)
6. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic shock syndrome Staphylococcus aureus isolates. Lancet 1981; 1:1017-1021
7. Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 2004; 42:2875-2876
8. Reingold AL, Broome CV, Gaventa S, Hightower AW. Risk factors for menstrual toxic shock syndrome: results of a multistate case-control study. Rev Infect Dis 1989; 11(Suppl 1):S35-41.
9. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705-711
10. Peterson ML, Ault K, Kremer MJ, et al. The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1. Infect Immun 2005; 73: 2164-2174 (Pubitemid 40470816) (Pubitemid 40470816)
11. Davis CC, Kremer MJ, Schlievert PM, Squier CA. Penetration of toxic shock syndrome toxin-1 across porcine vaginal mucosa ex vivo: permeability characteristics, toxin distribution, and tissue damage. Am J Obstet Gynecol 2003; 189:1785-1791
12. Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J Pharm Sci 2008; 97:9-21.
13. Larkin SM, Williams DN, Osterholm MT, Tofte RW, Posalaky Z. Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases. Ann Intern Med 1982; 96:858-864
14. Projan SJ, Brown-Skrobot S, Schlievert PM, Vandenesch F, Novick RP. Glycerol monolaurate inhibits the production of beta-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction. J Bacteriol 1994; 176:4204-4209 (Pubitemid 24226455)
15. Schlievert PM, Deringer JR, Kim MH, Projan SJ, Novick RP. Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob Agents Chemother 1992; 36:626-631
16. Schlievert PM, Case LC, Strandberg KL, Tripp TJ, Lin YC, Peterson ML. Vaginal Staphylococcus aureus superantigen profile shift from 1980 and 1981 to 2003, 2004, and 2005. J Clin Microbiol 2007; 45:2704-2707
17. Schlievert PM. Immunochemical assays for toxic shock syndrome toxin-1. Methods Enzymol 1988; 165:339-344 (Pubitemid 19014369) (Pubitemid 19014369)
18. Blomster-Hautamaa DA, Schlievert PM. Preparation of toxic shock syndrome toxin-1. Methods Enzymol 1988; 165:37-43. (Pubitemid 19014328) (Pubitemid 19014328)
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685
20. Schlievert PM, Case LC, Nemeth KA, et al. Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. Biochemistry 2007; 46:14349-14358
21. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7:95-102. (Pubitemid 23069039)
22. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:418-428
23. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42. (Pubitemid 39490046) (Pubitemid 39490046)
24. Plummer FA. Heterosexual transmission of human immunodeficiency virus type 1 (HIV): interactions of conventional sexually transmitted diseases, hormonal contraception and HIV-1. AIDS Res Hum Retroviruses 1998; 14(Suppl 1):S5-10.
25. Parsonnet J, Hansmann MA, Delaney ML, et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 2005; 43:4628-4634 (Pubitemid 41298254) (Pubitemid 41298254)
26. Schlievert PM, Osterholm MT, Kelly JA, Nishimura RD. Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome. Ann Intern Med 1982; 96: 937-940 (Pubitemid 12088904)
27. Kass EH, Kendrick MI, Tsai YC, Parsonnet J. Interaction of magnesium ion, oxygen tension, and temperature in the production of toxic-shocksyndrome toxin-1 by Staphylococcus aureus. J Infect Dis 1987; 155:812-815 (Pubitemid 17053009)
28. Schlievert PM, Blomster DA. Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. J Infect Dis 1983; 147:236-242
29. Hill DR, Brunner ME, Schmitz DC, et al. In vivo assessment of human vaginal oxygen and carbon dioxide levels during and post menses. J Appl Physiol 2005; 99:1582-1591
30. Yarwood JM, Schlievert PM. Oxygen and carbon dioxide regulation of toxic shock syndrome toxin 1 production by Staphylococcus aureus MN8. J Clin Microbiol 2000; 38:1797-1803 (Pubitemid 30253918)
31. Assimacopoulos AP, Strandberg KL, Rotschafer JH, Schlievert PM. Extreme pyrexia and rapid death due to Staphylococcus aureus infection: analysis of 2 cases. Clin Infect Dis 2009; 48:612-614
32. Pragman AA, Herron-Olson L, Case LC, et al. Sequence analysis of the Staphylococcus aureus srrAB loci reveals that truncation of srrA affects growth and virulence factor expression. J Bacteriol 2007; 189: 7515-7519 (Pubitemid 47557370) (Pubitemid 47557370)
33. Jarraud S, Cozon G, Vandenesch F, Bes M, Etienne J, Lina G. Involvement of enterotoxins G and I in staphylococcal toxic shock syndrome and staphylococcal scarlet fever. J Clin Microbiol 1999; 37:2446-2449 (Pubitemid 29337259)
34. Vetter SM, Schlievert PM. Glycerol monolaurate inhibits virulence factor production in Bacillus anthracis. Antimicrob Agents Chemother 2005; 49:1302-1305
35. Schlievert PM, Strandberg KL, Brosnahan AJ, et al. Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob Agents Chemother 2008; 52:4448-4454
36. Peterson ML, Schlievert PM. Glycerol monolaurate inhibits the effects of gram-positive select agents on eukaryotic cells. Biochemistry 2006; 45:2387-2397
37. Witcher KJ, Novick RP, Schlievert PM. Modulation of immune cell proliferation by glycerol monolaurate. Clin Diagn Lab Immunol 1996; 3:10-13 (Pubitemid 26041567)
38. Brosnahan AJ, Schaefers MM, Amundson WH, et al. Novel toxic shock syndrome toxin-1 amino acids required for biological activity. Biochemistry 2008; 47:12995-13003